Result of AGM

RNS Number : 2166D

HeiQ PLC

25 June 2021

 

25 June 2021

HeiQ Plc

("HeiQ" or "the Company")

Result of AGM

HeiQ (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, announces that at its Annual General Meeting held earlier today, Friday 25 June 2021, all resolutions were duly passed.

All proxy votes received in relation to resolutions at the AGM will be available shortly on the Company's website: www.HeiQ.com/investors .

For further information, please contact:

HeiQ Plc Carlo Centonze (CEO)	[phone]
Arlington Group Asset Management Limited (Financial Advisor and Joint Broker) Charles Cannon Brookes	[phone]
Cenkos Securities plc (Joint Broker) Stephen Keys / Callum Davidson	[phone]
SEC Newgate (Media Enquiries) Elisabeth Cowell / Megan Kovach	[phone] HeiQ@s ecnewgate .co.uk

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. It is an IP-rich pioneer which is at the forefront of global technology in the $10 billion antimicrobial fabrics and $24 billion textile chemicals market. It has also moved into the medical device, healthcare and probiotics markets, to help make hospitals and healthcare environments more hygienic.

HeiQ has created some of the most effective, durable and high-performance technologies and textile effects in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands. It has won multiple awards and gained a strong reputation for sustainability.

Led by an experienced management team, HeiQ rapidly researches new solutions for partners, quickly delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A. It has a healthy R&D pipeline containing over 40 projects.  

 

END

 

 

RAGUVOVRAVUNUAR